Publications 2018
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Cell death and differentiation 25(12), 2053 - 2070 (2018) [10.1038/s41418-018-0080-0]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
Klinischer Nutzen der molekularen Diagnostik pädiatrischer Hirntumore
Klinische Pädiatrie 230(6), 289 - 290 (2018) [10.1055/a-0750-8353]
BibTeX |
EndNote:
XML,
Text |
RIS
Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy.
OncoTarget 9(29), 20747-20760 (2018) [10.18632/oncotarget.25087]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series.
Klinische Pädiatrie 230(6), 305-313 (2018) [10.1055/a-0637-9653]
BibTeX |
EndNote:
XML,
Text |
RIS
Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance.
Scientific reports 8(1), 10039 (2018) [10.1038/s41598-018-28265-5]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
Archives of toxicology 92(8), 2649 - 2664 (2018) [10.1007/s00204-018-2234-8]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations.
Acta neuropathologica 136(2), 327 - 337 (2018) [10.1007/s00401-018-1871-6]
BibTeX |
EndNote:
XML,
Text |
RIS
Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Acta neuropathologica 136(2), 239 - 253 (2018) [10.1007/s00401-018-1865-4]
BibTeX |
EndNote:
XML,
Text |
RIS
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.
Acta neuropathologica 136(2), 181 - 210 (2018) [10.1007/s00401-018-1879-y]
BibTeX |
EndNote:
XML,
Text |
RIS
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
The lancet <London> / Oncology 19(6), 785 - 798 (2018) [10.1016/S1470-2045(18)30242-0]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.
Cell cycle 17(7), 811-822 (2018) [10.1080/15384101.2018.1442623]
BibTeX |
EndNote:
XML,
Text |
RIS
Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.
Molecular oncology 12(4), 495 - 513 (2018) [10.1002/1878-0261.12177]
Fulltext by Pubmed Central
BibTeX |
EndNote:
XML,
Text |
RIS
The landscape of genomic alterations across childhood cancers.
Nature <London> 555(7696), 321 - 327 (2018) [10.1038/nature25480]
BibTeX |
EndNote:
XML,
Text |
RIS
DNA methylation-based classification of central nervous system tumours.
Nature <London> 555(7697), 469 - 474 (2018) [10.1038/nature26000]
BibTeX |
EndNote:
XML,
Text |
RIS
Pharmacotherapeutic Management of Pediatric Lymphoma.
Pediatric drugs 20(1), 43 - 57 (2018) [10.1007/s40272-017-0265-x]
BibTeX |
EndNote:
XML,
Text |
RIS
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
Nature <London> 553(7686), 101 - 105 (2018) [10.1038/nature25169]
BibTeX |
EndNote:
XML,
Text |
RIS
BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma.
Journal of clinical oncology 36(1), 96 - 96 (2018) [10.1200/JCO.2017.75.8987]
BibTeX |
EndNote:
XML,
Text |
RIS
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
Pediatric blood & cancer 65(3), e26893 - (2018) [10.1002/pbc.26893]
BibTeX |
EndNote:
XML,
Text |
RIS